Medication-Related Osteonecrosis of the Jaws

Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs 

This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.

Sven Otto, MD, DDS, is a board-certified specialist in oral and maxillofacial surgery from Germany. He received both his dental degree (2002) and his medical degree (2006) from the University of Leipzig, Germany. Since 2006 he has been a resident at the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians University of Munich, Germany. One of his major fields of interest is bisphosphonate-related osteonecrosis of the jaw, especially the underlying pathophysiology. He has published numerous articles in leading scientific journals and has lectured nationally and internationally on this subject. In 2011, he was appointed group leader for 'Jaw bone and osteonecrosis of the jaw' in the Laboratory for Experimental Surgery and Regenerative Medicine (ExperiMed) of the Ludwig-Maximilians University of Munich.